Overview

  • Product name
    Anti-WSTF antibody [BAZ1H4H9]
    See all WSTF primary antibodies
  • Description
    Mouse monoclonal [BAZ1H4H9] to WSTF
  • Tested applications
    Suitable for: WB, Dot blot, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment (Human)

  • Positive control
    • HeLa, HAP1 whole cell lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab50987 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100. Predicted molecular weight: 171 kDa.
Dot blot Use at an assay dependent dilution.
ICC/IF 1/5.

Target

  • Function
    Atypical tyrosine-protein kinase that plays a central role in chromatin remodeling and acts as a transcription regulator. Involved in DNA damage response by phosphorylating 'Tyr-142' of histone H2AX (H2AXY142ph). H2AXY142ph plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress. Essential component of the WICH complex, a chromatin remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure. The WICH complex regulates the transcription of various genes, has a role in RNA polymerase I and RNA polymerase III transcription, mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes. In the complex, it mediates the recruitment of the WICH complex to replication foci during DNA replication. Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene. In the WINAC complex, plays an essential role by targeting the complex to acetylated histones, an essential step for VDR-promoter association.
  • Tissue specificity
    Ubiquitously expressed with high levels of expression in heart, brain, placenta, skeletal muscle and ovary.
  • Involvement in disease
    Note=BAZ1B is located in the Williams-Beuren syndrome (WBS) critical region. WBS results from a hemizygous deletion of several genes on chromosome 7q11.23, thought to arise as a consequence of unequal crossing over between highly homologous low-copy repeat sequences flanking the deleted region. Haploinsufficiency of BAZ1B may be the cause of certain cardiovascular and musculo-skeletal abnormalities observed in the disease.
  • Sequence similarities
    Belongs to the WAL family. BAZ1B subfamily.
    Contains 1 bromo domain.
    Contains 1 DDT domain.
    Contains 1 PHD-type zinc finger.
    Contains 1 WAC domain.
  • Developmental stage
    Expressed at equal levels in 19-23 weeks old fetal tissues.
  • Domain
    The N-terminal part (1-345), including the WAC domain and the C motif, mediates the tyrosine-protein kinase activity.
    The bromo domain mediates the specific interaction with acetylated histones.
  • Post-translational
    modifications
    Phosphorylated upon DNA damage, probably by ATM or ATR.
  • Cellular localization
    Nucleus. Accumulates in pericentromeric heterochromatin during replication. Targeted to replication foci throughout S phase via its association with PCNA.
  • Information by UniProt
  • Database links
  • Alternative names
    • baz1b antibody
    • BAZ1B_HUMAN antibody
    • Bromodomain adjacent to zinc finger domain protein 1B antibody
    • hWALP 2 antibody
    • hWALP-2 antibody
    • hWALP2 antibody
    • transcription factor WSTF antibody
    • Tyrosine-protein kinase BAZ1B antibody
    • WALP-2 antibody
    • WALP2 antibody
    • WBRS 9 antibody
    • WBRS-9 antibody
    • WBRS9 antibody
    • WBSC 10 antibody
    • WBSC-10 antibody
    • WBSC10 antibody
    • WBSCR10 antibody
    • WBSCR9 antibody
    • Williams Beuren syndrome chromosome region 9 protein antibody
    • Williams syndrome transcription factor antibody
    • Williams-Beuren syndrome chromosomal region 10 protein antibody
    • Williams-Beuren syndrome chromosomal region 9 protein antibody
    • WSTF antibody
    see all

Anti-WSTF antibody [BAZ1H4H9] images



  • Predicted band size : 171 kDa
    Additional bands at : 175 kDa. We are unsure as to the identity of these extra bands.

    Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: WSTF knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lanes 1 - 3: Merged signal (red and green). Green - ab50987 observed at 175 kDa. Red - loading control, ab176560, observed at 52kDa.

    Ab50987 was shown to recognize WSTF in wild-type HAP1 cells along with additional cross-reactive bands. No band was observed when WSTF knockout samples were used. Wild-type and WSTF knockout samples were subjected to SDS-PAGE. ab50987 and 176560 (loading control to alpha-tubulin) were diluted 1/100 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed withGoat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772 and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777 secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

  • Anti-WSTF antibody [BAZ1H4H9] (ab50987) at 1/100 dilution + HeLa whole cell lysate at 25 µg

    Secondary
    Anti mouse IgG antibody at 1/2500 dilution

    Predicted band size : 171 kDa
    Observed band size : 171 kDa
  • Ab50987 at 1/5 dilution staining HeLa cells; visualised with AlexaFluor®488 Goat Anti-mouse IgG at 1/200 dilution.

References for Anti-WSTF antibody [BAZ1H4H9] (ab50987)

This product has been referenced in:
  • Liu Y  et al. KRASG12 mutant induces the release of the WSTF/NRG3 complex, and contributes to an oncogenic paracrine signaling pathway. Oncotarget 7:53153-53164 (2016). Read more (PubMed: 27449290) »

See 1 Publication for this product

Product Wall

Application
Western blot
Sample
Human Cell lysate - nuclear (Vascular smooth muscle cell)
Gel Running Conditions
Reduced Denaturing (6% gel)
Loading amount
20 µg
Specification
Vascular smooth muscle cell
Blocking step
Milk as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C
Username

Abcam user community

Verified customer

Submitted Feb 22 2017

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up